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Background: Reliable population-based data on HIV infection and AIDS mortality in sub-Saharan Africa are
scanty, even though that is the region where most of the world’s AIDS deaths occur. There is therefore a great
need for reliable and valid public health tools for assessing AIDS mortality.
Objective: The aim of this article is to validate the InterVA-4 verbal autopsy (VA) interpretative model within
African populations where HIV sero-status is recorded on a prospective basis, and examine the distribution of
cause-specific mortality among HIV-positive and HIV-negative people.
Design: Data from six sites of the Alpha Network, including HIV sero-status and VA interviews, were pooled.
VA data according to the 2012 WHO format were extracted, and processed using the InterVA-4 model into
likely causes of death. The model was blinded to the sero-status data. Cases with known pre-mortem HIV
infection status were used to determine the specificity with which InterVA-4 could attribute HIV/AIDS as a
cause of death. Cause-specific mortality fractions by HIV infection status were calculated, and a person-time
model was built to analyse adjusted cause-specific mortality rate ratios.
Results: The InterVA-4 model identified HIV/AIDS-related deaths with a specificity of 90.1% (95% CI
88.791.4%). Overall sensitivity could not be calculated, because HIV-positive people die from a range of
causes. In a person-time model including 1,739 deaths in 1,161,688 HIV-negative person-years observed and
2,890 deaths in 75,110 HIV-positive person-years observed, the mortality ratio HIV-positive:negative was
29.0 (95% CI 27.131.0), after adjustment for age, sex, and study site. Cause-specific HIV-positive:negative
mortality ratios for acute respiratory infections, HIV/AIDS-related deaths, meningitis, tuberculosis, and
malnutrition were higher than the all-cause ratio; all causes had HIV-positive:negative mortality ratios
significantly higher than unity.
Conclusions: These results were generally consistent with relatively small post-mortem and hospital-based
diagnosis studies in the literature. The high specificity in cause of death attribution achieved in relation to HIV
status, and large differences between specific causes by HIV status, show that InterVA-4 is an effective and valid
tool for assessing HIV-related mortality.
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A
s the HIV/AIDS pandemic has evolved, reliable
assignment of cause of death for people who have
lived with the infection has been a persistent
difficulty. Although there is no doubt about increased
mortality risks associated with HIV infection (1), in
settings where people frequently die outside the scope
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of effective medical services, or where the disease con-
tinues to carry some stigma, there may be inadequate
information or unwillingness to document HIV/AIDS as
a cause of death (2). The situation is further complicated
by the interactions between HIV infection and other
diseases, whereby clear manifestations of AIDS may not
be major features of final illnesses among HIV-positive
people, particularly among those receiving treatment (3).
As a result of these difficulties, reliable community-
based data on HIV/AIDS-related mortality, particularly
in highly HIV-infected areas in Africa, have been very
scanty. Modelled estimates of AIDS mortality at national
and global levels have therefore fluctuated widely as the
pandemic has progressed, and despite improving estima-
tion methods, details remain uncertain (4). It is widely
recognised that where deaths are not routinely certified as
to their cause, verbal autopsy (VA) is the interim method
of choice for documenting cause-specific mortality pat-
terns (5). Although VA has been variously implemented
in areas of high HIV infection and AIDS mortality,
VA procedures have generally not been validated at the
individual level against measurable outcomes such as
HIV sero-status, leading to suppositions that VA is an
unreliable approach for identifying HIV/AIDS deaths (6).
Some sero-validation studies have been implemented in
the context of HIV treatment centres (7), but not on a
population basis, where there is normally no informa-
tion on pre-mortem infection status. Other studies have
compared VA results on AIDS mortality from different
sources, such as between InterVA and physician inter-
pretation, but in the absence of any absolute standard for
comparison (8).
In a collaboration between the Health Metrics Net-
work (9), the Alpha Network (10), and the INDEPTH
Network (11), one aim was to validate measurement of
AIDS mortality in documented population surveillance
sites in which HIV infection status was gathered pro-
spectively. This initiative coincided with the development
of the InterVA-4 model for interpreting VA interview
material, the latest model in the InterVA series (12) which
corresponds to the 2012 WHO VA tool (13) and is freely
available at www.interva.net.
The aim of this article is to analyse InterVA-4 inter-
pretations of routinely gathered VA material from six
population surveillance sites in Africa, as shown in Fig. 1,
against known HIV sero-status. This will permit an
assessment of the specificity of the InterVA-4 model
for the assignment of HIV/AIDS-related deaths, as well
as investigating differences in cause of death patterns
according to HIV infection as a risk factor for mortality
in African populations.
Methods
The basic modes of operation of the six population
surveillance sites involved, of which all are members of
the Alpha Network and some are members of the
INDEPTH Network, have been described previously
(1419). These sites are located on a northsouth transect
of some 3,500 km through eastern and southern Africa.
Briefly, all the sites followed a particular geographically
defined adult population longitudinally, capturing vital
events as well as the results of HIV sero-testing. Exact
procedures for following up deaths and carrying out VA
interviews (interviews with relatives or other witnesses
of a death about the circumstances and symptoms of
the final illness) varied to some extent between sites, and
have developed over time. Intervals between deaths and
VA follow-up vary across sites, ranging up to 2 years in
Manicaland. For the purposes of this study, no special
procedures were implemented, and it was important to
make use of all available archived VA interview material,
most of which was collected before current standards for
undertaking VAs were established. Nevertheless, for the
purposes of standard comparison over time and between
sites, all the archived VA data were converted into the
WHO 2012 standard VA format, which corresponds
exactly to the input parameters needed for the InterVA-
4 interpretative model (13). In some cases, desirable data
items were not available in the VA archives, in which case
they remained absent from the InterVA-4 input. However,
the InterVA-4 model was deliberately designed to deter-
mine cause of death on the basis of available data items,
and does not make any distinction between negative and
missing values for individual parameters.
The data used for this validation study relate to 17,560
adult deaths (15 years and over) occurring between 1990
and 2011, all of which were successfully documented in
VA interviews, from the six population sites shown in
Fig. 1. Overall 5,029 (28.6%) of these cases had one or
more documented HIV sero-test results sometime before
death. Any recorded positive test was taken as evidence
of HIV infection, and person-time from the test date
onwards categorised as HIV positive. Recorded negative
tests were only considered in relation to cause of death if
documented within 5 years of death, and the time period
between testing and death was recorded individually.
HIV-negative person-time was calculated starting from
any negative test result, and running until the first of: a
positive test result, death, or the fifth anniversary of the
negative test. In the majority of the VA interviews con-
ducted, a specific question was included as to whether,
to the knowledge of the respondent, the deceased had any
history of HIV/AIDS diagnosis or treatment. If such a
declaration was made in the VA interview for someone
who had only documented a negative test, then those
cases were put into a separate positive category, on the
grounds that they had most likely sero-converted since
testing. Similarly, a further positive category was defined
for those who had not been sero-tested within 5 years of
death, but were declared in VA interviews to have had a
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diagnosis of HIV. Specific questions about existing HIV
diagnoses were not included in the VA instruments used
in the Manicaland and Masaka sites. Those cases which
had no sero-test recorded or whose most recent negative
test result was recorded more than 5 years before death,
and for which no diagnosis of HIV or AIDS was declared
at VA, remained in an unknown status group. For the
data input to the InterVA-4 model, if a diagnosis of
HIV or AIDS was reported in the VA interview, then the
corresponding input indicator was flagged, as would
normally happen in the absence of serological data. In
this study, the InterVA-4 model was not provided with
any information on sero-test results, so that the cause of
death assignment was blinded to those additional data.
Input indicators for the InterVA-4 model, as defined in
the WHO 2012 VA tool, were retrospectively extracted
from VA archives in each participating site. These were
accumulated into a pooled dataset which was split into
low malaria (South Africa) and high malaria (other sites)
for InterVA-4 processing. This is in line with recommen-
dations in the InterVA-4 documentation of high malaria
corresponding to populations where approximately 1%
or more of all deaths are due to malaria. Cause of death
assignments (up to three per case) was made with asso-
ciated likelihoods. Where input data are scanty, lower
likelihood outputs typically result. As previously recom-
mended with InterVA outputs, these data were analysed
by taking the likelihoods of the assigned causes for each
case and attributing any residual proportion of the death
as indeterminate (12). InterVA-4 outputs were read into
Stata 12 to process cause of death likelihoods. Conse-
quently fractional causes of death arose, which have
been aggregated in the following analyses. Cause of death
categories assigned by InterVA-4 corresponds to the
WHO 2012 VA standard cause of death groupings, one
of which is ‘HIV/AIDS-related death’ (5). Specific causes
Fig. 1. Participating Alpha Network sites, showing numbers of deaths with verbal autopsies, by HIV status.
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Table 1. Numbers of adult deaths (n17,560) and proportions assigned by InterVA-4 as HIV/AIDS related, by age, sex, time period, and site, according to HIV status
HIV-negative test before death, at: HIV-positive on the basis of:
011 months 1223 months 2459 months Overall
Positive test
and positive VA
Positive test,
not VA
No test,
positive VA
Prev. negative
test, positive VA Overall
HIV status
unknown
Overall
Deaths 860 516 530 1,906 1,010 1,983 2,204 130 5,327 10,327
% HIV/AIDS 8.4 9.4 12.8 9.9 45.8 36.7 43.4 43.0 41.4 15.4
1549 years
Deaths 314 266 282 862 719 1,627 1,465 67 3,878 5,414
% HIV/AIDS 16.1 13.9 20.1 16.7 51.2 39.3 49.0 55.1 45.4 23.8
5064 years
Deaths 186 86 95 367 89 235 204 18 546 1,570
% HIV/AIDS 6.8 7.5 8.2 7.3 37.4 32.6 45.4 48.1 38.7 12.8
65 years
Deaths 360 164 153 677 202 121 535 45 903 3,343
% HIV/AIDS 2.6 3.2 2.0 2.6 30.4 10.7 27.1 22.8 25.4 3.0
Male
Deaths 439 288 286 1,013 416 831 1,020 71 2,338 4,935
% HIV/AIDS 5.1 7.3 6.4 6.1 39.9 27.9 38.0 39.9 34.8 12.4
Female
Deaths 421 228 244 893 594 1,152 1,184 59 2,989 5,392
% HIV/AIDS 12.0 12.1 20.3 14.3 50.0 43.1 48.0 46.6 46.5 18.2
Pre-2002
Deaths 110 78 45 233 49 374 326 8 757 1,953
% HIV/AIDS 24.6 18.1 26.5 22.8 70.1 58.8 53.0 85.1 57.3 20.6
200207
Deaths 299 200 253 752 545 1,173 1,199 59 2,976 6,338
% HIV/AIDS 10.9 12.4 15.7 12.9 51.6 36.1 47.4 55.0 43.9 15.7
2008 on
Deaths 451 238 232 921 416 436 679 63 1,594 2,036
% HIV/AIDS 2.9 4.1 6.9 4.2 35.5 19.5 31.7 26.3 29.1 9.3
Karonga
Deaths 96 27 17 140 43 14 199 2 258 932
% HIV/AIDS 4.2 3.3 0 3.5 27.5 0 67.9 0 57.0 15.5
Kisesa
Deaths 97 127 141 365 68 224 90 11 393 914
% HIV/AIDS 17.1 11.9 11.5 13.1 91.1 40.3 84.2 72.7 60.1 20.4
Manicaland
Deaths 60 60 84 204  639   639 186
% HIV/AIDS 31.6 29.6 38.4 33.8  58.1   58.1 57.8
Masaka
Deaths 129 22 24 175  101   101 134
% HIV/AIDS 27.0 21.0 7.8 23.6  57.5   57.5 34.6
Rakai
Deaths 78 77 67 222 507 230 921 76 1,734 1,424
% HIV/AIDS 3.1 5.4 7.6 5.3 49.0 18.8 41.3 45.6 40.8 6.8
uMkhanyakude
Deaths 400 203 197 800 392 775 994 41 2,202 6,737
% HIV/AIDS 1.7 2.9 6.2 3.1 35.8 21.3 36.7 32.2 31.0 15.0
The InterVA-4 model was ‘blinded’ to the HIV sero-status data, only taking into account a history or diagnosis of HIV/AIDS if reported in the VA interview.
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which occurred very rarely were subsumed into the
relevant residual categories.
Using data for individual residence episodes observed
in the six participating sites, a Poisson regression model
was constructed in Stata 12, using the sero-test results
and cause of death findings to facilitate analysing cause-
specific mortality fractions and rates by HIV infection
status, allowing adjustment by age group, sex, and site.
Results
Table 1 shows the total number of deaths, split by age
group, sex, time period, and site, according to HIV
infection status. Individuals who had reported negative
tests are divided according to time period between testing
and death, and positive individuals categorised according
to the source of information, including recorded positive
tests and diagnoses reported in VA interviews. Each cell
shows the total number of deaths and the percentage
of those assigned by InterVA-4 to ‘HIV/AIDS-related
death’. It is not inevitable that all causes of death among
HIV-positive people are HIV/AIDS related. Here, the
overall proportion of deaths among the HIV positive
attributed as HIV/AIDS-related was 41.4%. Deaths
under the HIV-negative categories should, in principle,
have no HIV/AIDS-related deaths assigned, and so
those that are recorded must arise from sero-conversion
after testing, false-positive assignments by the model, or
errors in test records. These cases amounted to 9.9%
of the HIV-negative deaths. The overall specificity with
which InterVA-4 identified HIV/AIDS-related deaths was
90.1%. Table 2 shows the specificities by age group, sex,
time period, and site.
For cases where HIV sero-status was known before
death, it is possible to calculate cause-specific mortality
fractions and rates according to HIV-negative and HIV-
positive person-years observed. Table 3 shows results
of this approach applied to 1,739 deaths in 1,161,688
HIV-negative person-years observed and 2,890 deaths in
75,110 HIV-positive person-years observed. The crude
mortality ratio was thus 25.7, and on this basis 96% of
the mortality in the HIV-positive group was excess over
what would be expected in the absence of HIV. HIV-
positive deaths attributed to HIV/AIDS, pneumonia,
and tuberculosis accounted for most of this excess. For
all causes, mortality rates were higher among the HIV-
positive group, and for many the rate ratios were con-
siderably greater than unity. A Poisson regression model
was used to estimate cause-specific mortality ratios adjus-
ted for age group, sex, and site. The all-cause adjusted
mortality ratio was 29.0 (95% CI 27.131.0). Cause-
specific adjusted mortality ratios, with 95% confidence
intervals, are shown in Fig. 2. For all causes, HIV-positive
people had significantly higher mortality than HIV-
negative people (lower limits of 95% CIs for mortality
ratios1), but with considerable variation in ratios
between causes, as shown on the horizontal logarithmic
scale of Fig. 2.
Discussion
Overall, these results show that the InterVA-4 detects
typical AIDS deaths in adults with high specificity,
without the model having access to sero-status data.
Exactly what constitutes a typical AIDS death is not easy
to define, even though it is clear that the clinical expertise
encapsulated within the InterVA model is, to a large
extent, successfully identifying symptom patterns that are
strongly associated with final illnesses in HIV-infected
people, which might reasonably fall into the category
of ‘HIV/AIDS-related death’. Nevertheless, HIV infec-
tion also clearly affects many other cause-specific mor-
tality rates. Therefore, it is not possible to calculate a
single parameter for sensitivity, because there is no single
cause of death that inevitably follows HIV infection, and
it is also evident that patterns of cause of death do vary
considerably between the HIV-negative and HIV-positive
groups, again without the model having access to those
data.
Achieving 90% specificity overall in identifying typical
HIV/AIDS-related deaths with the InterVA-4 model,
although blinding the model to sero-status, is an impor-
tant achievement. Interestingly, the number of false posi-
tives recorded only slightly exceeded the number of cases
with a negative test during the previous 5 years where a
diagnosis of HIV was subsequently declared in the VA
interview. Because it is clear that HIV positivity is by no
means universally disclosed in VA interviews (here not
disclosed in 37.2% of the HIV-positive cases), it is likely
Table 2. Specificities for InterVA-4 assignment of
HIV/AIDS-related deaths, based on people with a negative
HIV test result in the 5-year period before death
Specificity
95% confidence
interval
Overall 90.1 88.791.4
1549 years 83.3 80.685.6
Age group 5064 years 92.7 89.594.9
65 years 97.4 95.998.4
Sex
Male 94.0 92.395.3
Female 85.7 83.387.9
19902002 77.2 71.482.1
Period 20022007 87.1 84.589.3
20082011 95.8 94.396.9
Study site
Karonga 96.5 92.098.5
Kisesa 86.9 83.090.0
Manicaland 66.2 59.572.3
Masaka 87.0 81.291.2
Rakai 94.8 91.097.0
uMkhanyakude 95.9 94.397.1
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that at least a proportion of the false positives identified
here were in fact true positives by the time of death. The
generally lower proportions of false positives who tested
negative closer to their time of death also support this
possibility. The recall period from death to VA interview
varied by site, and this may have influenced specificity in
some sites.
Although HIV infection represents a substantial risk
factor for mortality from many causes, as shown in Fig.
2, it was also the case numerically, as shown in Table 3,
that the overwhelming majority of deaths (73.9%) among
HIV-infected people were assigned to acute respira-
tory infections, AIDS, or pulmonary TB. However, it is
equally clear that not all of the 25-fold overall mortality
risk among the HIV infected is accounted for by these
main causes. As anti-retroviral therapy (ART) coverage
increases in scope and effectiveness, the overall mortality
risk associated with HIV infection is likely to decrease,
but at the same time there is likely to be increasing
diversity in cause of death among the HIV infected.
Monitoring these changes in cause-specific mortality at
the community level, using a standardised tool such as
InterVA-4, will be an important strategy for understand-
ing the future trajectory of the HIV pandemic.
Cause of death patterns for HIV-positive people in
African populations are generally not well documented.
Table 3. InterVA-4 causes of death, cause-specific mortality fractions, and adjusted mortality ratios by known HIV status for
1,739 deaths in 1,161,688 HIV-negative person-years observed and 2,890 deaths in 75,110 HIV-positive person-years observed
Cause-specific mortality
fraction (%)
Mortality rate per
1,000 per year
WHO VA cause of death by InterVA-4 HIV negative HIV positive HIV negative HIV positive Mortality rate ratio
01.02 Acute respiratory infections, including pneumonia 4.16 6.33 0.06 2.44 39.1
01.03 HIV/AIDS-related death 10.60 38.89 0.16 14.96 94.3
01.04 Diarrhoeal diseases 1.07 0.36 0.02 0.14 8.6
01.05 Malaria 3.17 1.95 0.05 0.75 15.8
01.07 Meningitis and encephalitis 1.12 1.33 0.02 0.51 30.5
01.09 Pulmonary tuberculosis 11.54 28.71 0.17 11.05 63.9
01.99 Other and unspecified infectious disease 1.68 1.54 0.03 0.59 23.5
02.01 Oral neoplasms 0.49 0.37 0.01 0.14 19.2
02.02 Digestive neoplasms 3.92 1.98 0.06 0.76 13.0
02.03 Respiratory neoplasms 2.58 0.60 0.04 0.23 6.0
02.04 Breast neoplasms female 0.51 0.19 0.01 0.07 9.6
02.06 Reproductive neoplasms female 1.61 0.90 0.02 0.34 14.3
02.99 Other and unspecified neoplasms 1.85 0.56 0.03 0.21 7.7
03.01 Severe anaemia 0.80 0.11 0.01 0.04 3.7
03.02 Severe malnutrition 0.35 0.41 0.01 0.16 29.7
03.03 Diabetes mellitus 3.75 0.73 0.06 0.28 5.0
04.01 Acute cardiac disease 1.62 0.40 0.02 0.15 6.4
04.02 Stroke 4.73 0.40 0.07 0.15 2.2
04.99 Other and unspecified cardiac disease 5.31 0.69 0.08 0.27 3.4
05.01 Chronic obstructive pulmonary disease 2.82 0.17 0.04 0.07 1.6
05.02 Asthma 1.59 0.49 0.02 0.19 8.0
06.01 Acute abdomen 6.38 2.79 0.10 1.07 11.2
98 Other and unspecified non-communicable disease 2.45 0.44 0.04 0.17 4.6
12.01 Road traffic accident 2.71 0.47 0.04 0.18 4.4
12.08 Intentional self-harm 0.99 0.14 0.01 0.05 3.6
12.09 Assault 6.18 1.29 0.09 0.50 5.4
12.99 Other and unspecified external cause of death 1.57 0.23 0.02 0.09 3.8
09.03 Pregnancy-induced hypertension 0.38 0.14 0.01 0.05 9.1
09.04 Obstetric haemorrhage 1.09 0.15 0.02 0.06 3.6
09.06 Pregnancy-related sepsis 0.28 0.17 0.00 0.07 15.7
09.99 Other and unspecified maternal cause of death 0.37 0.33 0.01 0.13 22.9
99 Indeterminate 12.31 6.74 0.18 2.59 14.1
All causes 100 100 1.50 38.48 25.7
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An autopsy series from South Africa showed that the top
three ranked causes of death among HIV-positive people
were TB, pneumonia, and meningitis (20) and the same
pattern was observed in a smaller series in Uganda (21).
A review of autopsy studies in Africa showed that TB,
pneumonia, and meningitis were major causes of death
among HIV-positive people, though there were major
discrepancies between hospital causes of death and
pathology findings (22). Similar causes of death patterns
have been observed in hospital patient series in Thailand
(23) and South Africa (24). Comparisons between various
studies are sometimes difficult to make because of a
variety of understandings of what ‘AIDS deaths’ consti-
tute against a background of specific causes of death such
as pneumonia and meningitis among the HIV positive.
The very different nature of HIV epidemiology in other
settings, such as Taiwan (25) and Korea (26), also make
comparison with African populations difficult. However,
the VA findings from this study are broadly consistent
with these other cause of death findings among HIV-
positive people.
Lopman et al. proposed a number of key symptoms
that were associated with HIV infection (27), many of
which are directly reflected in the causes of death with
high rate ratios associated with HIV positivity here. The
largest numbers of relevant symptoms involved relate to
pulmonary TB and acute respiratory infections, although
there are very high rate ratios for symptoms associated
with some rarer causes as well. An indirect comparison
can also be made with excess risks among transplant
patients who are artificially immunosuppressed to counter-
rejection. A population-based study in Sweden showed
very high incidence rates for some specific cancers among
immunosuppressed transplant patients: lip [standardised
incidence ratio (SIR) 53]; mediastinum (SIR 43); vulva
and vagina (SIR 21); and non-melanoma skin cancer
(SIR 56) (28). Although VA does not readily enable
highly detailed site-specific identification of neoplasms,
the very high mortality rate ratios for oral and female
reproductive neoplasms in Table 3 are not inconsistent
with these findings from Sweden.
As might be expected in a multi-site study, there were
some differences observed between sites, and these are
likely to be due to a combination of procedural and
methodological differences, as well epidemiological and
geographical variation. In many ways recovering VA data
retrospectively from a variety of instruments is a worst-
case scenario, even if a realistic one; at least it is very
unlikely to have enhanced the performance of cause of
death assignment. We would expect that VA interviews
conducted directly under the WHO 2012 standard pro-
tocol would yield higher quality data. A further impor-
tant factor that will have changed over time, but is not
documented here, is the uptake of ART. As yet it remains
an open question as to what the cause of death patterns
may turn out to be among HIV-positive people who have
1 10 100
mortality rate ratio HIV+ve : HIV-ve 
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02.02 Digestive neoplasms
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03.03 Diabetes mellitus
04.01 Acute cardiac disease
04.02 Stroke
04.99 Other and unspecified cardiac dis
05.01 Chronic obstructive pulmonary dis
05.02 Asthma
06.01 Acute abdomen
98 Other and unspecified NCD
12.01 Road traffic accident
12.08 Intentional self-harm
12.09 Assault
12.99 Other and unspecified external CoD 
09.03 Pregnancy-induced hypertension
09.04 Obstetric haemorrhage
09.06 Pregnancy-related sepsis
09.99 Other and unspecified maternal CoD 
99 Indeterminate
ALL CAUSES
Fig. 2. Cause-specific mortality rate ratios for HIV-positive: HIV-negative deaths, based on Poisson multivariate modelling of
mortality rates, adjusted for age group, sex, and study site, showing 95% confidence intervals (CIs). The all-cause adjusted
mortality rate ratio was 29.0 (95% CI 27.131.0), represented by the vertical axis.
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taken ART for many years or even decades. It already
appears here that there was a lower proportion of typical
AIDS deaths among all categories of HIV positivity in
the later periods, and this may well be due, at least in
part, to treatment effects. The WHO 2012 VA standard
(and hence InterVA-4) does not include any specific item
on ART, though this may be something that needs to be
incorporated in a future version.
Despite the difficulties in making precise comparisons
of causes of death, the major differences between cause-
specific adjusted mortality rate ratios by HIV status
generated by InterVA-4 are important, given the blinding
of the model to HIV sero-status. Unlike the relatively
small post-mortem series that have been reported, this
study of nearly 5,000 VAs on deaths of known HIV status
allows examination of relatively rare causes of death in
relation to HIV, as well as confirming the major causes of
death related to the risk of HIV infection. Although VA
as an overall approach, and the InterVA-4 model as a
specific tool for determining cause of death, cannot be
regarded as equivalent to undertaking post-mortems, this
study shows that VA can realistically be applied in large-
scale community-based settings and yield cause of death
results that are consistent with other approaches, success-
fully differentiating by HIV status. In addition, the use of
a standardised model such as InterVA-4 for interpreting
VA material obviates the possibility of local differences in
interpretation. We conclude that InterVA-4 is an effective
and valid public health tool for assessing mortality in
relation to HIV infection and deaths due to AIDS.
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